Overall Survival of CDK4/6-Inhibitor–Based Treatments in Clinically Relevant Subgroups of Metastatic Breast Cancer: Systematic Review and Meta-AnalysisFrancesco Schettini, Daniele Generali, PierFranco Conte et al.|JNCI Journal of the National Cancer Institute|2020Cited by 102
Poly (ADP-ribose) polymerase inhibitors in solid tumours: Systematic review and meta-analysisFrancesco Schettini, Daniele Generali, Fabiola Giudici et al.|European Journal of Cancer|2021Cited by 65
Endocrine-Based Treatments in Clinically-Relevant Subgroups of Hormone Receptor-Positive/HER2-Negative Metastatic Breast Cancer: Systematic Review and Meta-AnalysisFrancesco Schettini, Daniele Generali, Mario Giuliano et al.|Cancers|2021Cited by 35
Survival Following CDK4/6 Inhibitor Therapy for Hormone Receptor–Positive, <i>ERBB2</i>–Negative Metastatic Breast CancerPier Paolo Maria Berton Giachetti, Carmen Criscitiello, Stefania Morganti et al.|JAMA Network Open|2025Cited by 11
Comparative efficacy between real-world and randomized studies of palbociclib+endocrine therapy in HR-positive/HER2-negative metastatic breast cancer: systematic review and meta-analysisFrancesco Schettini, Daniele Generali, Sabrina Nucera et al.|JNCI Cancer Spectrum|2025Cited by 1